Skip to Main Content

To be an effective venture capital investor in biotech, you’ve got to have a keen eye for red flags. After all, you don’t want to miss the telltale signs that a startup might be a disaster in the making and make an investment you’ll regret.

Greg Yap, a Silicon Valley venture capital investor, is in the business of looking for red flags. Yap has spent most of his career on the operating side in biotech, including a stint running Roche’s cancer diagnostics business.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!